Safety Study of Tezepelumab in Adult and Adolescent Participants With Severe Asthma (PASSAGE)
- Study HIC#:2000034629
- Last Updated:06/26/2024
The PASSAGE Study will investigate how Tezepelumab (TEZSPIRE®) works in people with severe asthma and in under-represented populations, the information we collect might help others with asthma in the future. The time commitment for the PASSAGE Study is about a year. Patients will be asked to attend monthly study visits to receive the study drug injections. Study visits will also consist of lung function tests, blood draws, and patients will be asked to fill in questionnaires at different times through the duration of the study. Tezepelumab (TEZSPIRE®) is currently approved in the US for adults and adolescents aged 12 years and older.
- Age18 years - 130 years
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Katie Spaulding
- Phone Number: 1-203-737-5572
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
The PASSAGE Study will investigate how Tezepelumab (TEZSPIRE®) works in people with severe asthma and in under-represented populations, the information we collect might help others with asthma in the future. The time commitment for the PASSAGE Study is about a year. Patients will be asked to attend monthly study visits to receive the study drug injections. Study visits will also consist of lung function tests, blood draws, and patients will be asked to fill in questionnaires at different times through the duration of the study. Tezepelumab (TEZSPIRE®) is currently approved in the US for adults and adolescents aged 12 years and older.
Eligibility Criteria
Inclusion Criteria:
- Male or female ages 12 and older
- Documented physician-diagnosed asthma for at least 12 months prior to Visit 1
- Documented treatment with medium- to high-dose ICS
- Use of additional asthma maintenance controller medication
- Documented history of at least 2 asthma exacerbations during the 12 months prior to Visit 1
- Currently receiving care from specialist physicians (e.g., pulmonologists and/or allergists) at the Investigator’s or sub-investigator’s site.
